



## IBA Signs Three Major Contracts for the Supply of Rhodotron® Electron Beam Sterilization in Asia

- Further success for IBA in expanding its business in Asia
- Value of contracts worth approx. EUR 10 million to IBA

**Louvain-La-Neuve, Belgium, October 11<sup>th</sup>, 2012** - IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces that its medical and industrial accelerators business unit has signed three new contracts for the supply of IBA's Rhodotron® Electron Beam Sterilization in Asia. The value of the three contracts represents approximately EUR 10 million in revenue to IBA.

These contracts demonstrate IBA's continued success in Asia and strengthens IBA's presence in emerging markets. The supplied Rhodotrons will primarily be used for the sterilization of medical devices using electron beam technology. The key advantage of IBA's technology in comparison to radioactive or chemical based sterilization processes is that IBA's Rhodotron® Electron Beam process is fast and free from any contamination by chemicals and radioactive materials.

**Olivier Legrain, Chief Executive Officer of IBA commented:** "The growing Asian markets and the drive in the region for better sterilization processes represent a good opportunity for IBA's medical and industrial accelerators business. We will continue to focus on bringing our leading edge technologies to this region and look forward to announcing further successes later in the year."

### About IBA's Rhodotron®

Thanks to its unique high power, the Rhodotron® is the only electron beam accelerator able to process large scale sterilization volumes. IBA has sold more than 30 Rhodotrons worldwide to major medical device manufacturers and sterilization service centers. More information about Electron Beam and X-ray Sterilization can be found at [www.iba-sterilization.com](http://www.iba-sterilization.com)

### About IBA

IBA (Ion Beam Applications S.A.), is the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.



Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. Further information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

**For further information please contact:**

**IBA**

Jean-Marc Bothy  
Chief Financial Officer  
+32 10 475 890  
[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

Thomas Ralet  
Vice-President Corporate Communication  
+32 10 475 890  
[thomas.ralet@iba-group.com](mailto:thomas.ralet@iba-group.com)

**For media and investor enquiries:**

**M:Communications**

Mary-Jane Elliott, Amber Bielecka,  
Claire Dickinson  
+44 (0) 207 920 2333  
[IBA@mcomgroup.com](mailto:IBA@mcomgroup.com)